Cortexyme reports q4 loss per share of $0.46

Cortexyme announces fourth quarter and full year 2019 financial results and provides business update.q4 loss per share $0.46.q4 earnings per share estimate $-0.40 -- refinitiv ibes data.cortexyme - cash, cash equivalents, & short and long-term marketable securities as of dec 31, 2019, were $116.6 million.cortexyme - is now screening its proprietary library of small molecules for a possible treatment for coronaviruses.
QNCX Ratings Summary
QNCX Quant Ranking